FDA Classifies Bacillus Protein Detection Test as Class II Medical Device
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This rule classifies a simple in vitro diagnostic test that detects secreted proteins from Bacillus species in human clinical samples as a Class II medical device. That means the device can be regulated with special controls rather than the stricter Class III premarket approval pathway. The change mainly affects medical device makers, clinical laboratories, and healthcare providers that develop, distribute, or use this type of diagnostic test. FDA says the classification should support safety and effectiveness while reducing regulatory burden and improving access to innovative diagnostic tools.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Classifies the Bacillus secreted-protein diagnostic test as a Class II medical device
- Applies special controls to manage safety and effectiveness risks
- Reduces the regulatory burden compared with automatic Class III classification
Obligations
What this law requires
Simple in vitro diagnostic devices that detect secreted proteins from Bacillus species in human clinical samples must be regulated as Class II medical devices subject to FDA special controls rather than Class III premarket approval classification.